An Open-label Randomized Multicenter Phase III Clinical Study Comparing Safety and Efficacy of Algeron (Cepeginterferon Alfa-2b) and and PegIntron (Peginterferon Alfa-2b) in Combination With Ribavirin as Combined Treatment of Chronic Hepatitis C in Human Immunodeficiency Virus-1 Infected Patients

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Biocad
ClinicalTrials.gov Identifier:
NCT02103439
First received: April 1, 2014
Last updated: July 22, 2015
Last verified: July 2015
  Purpose

The purpose of the study is to demonstrate the noninferiority of Algeron in combination with ribavirin compared to PegIntron in combination with ribavirin in treatment of chronic hepatitis C in Human Immunodeficiency Virus-1 infected patients


Condition Intervention Phase
Hepatitis
Hepatitis C
Hepatitis C/ Human Immunodeficiency Virus Coinfection
Drug: Algeron
Drug: PegIntron
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Multicenter Open-label Randomized, Comparative Clinical Study to Evaluate Efficacy and Safety of Algeron (Cepeginterferon Alfa-2b, CJSC "BIOCAD", Russia) With Ribavirin Compared to PegIntron (Peginterferon Alfa-2b, Schering-Plough Labo N.V., Belgium) With Ribavirin in Treatment of Chronic Hepatitis C in Human Immunodeficiency Virus-1 Infected Patients

Resource links provided by NLM:


Further study details as provided by Biocad:

Primary Outcome Measures:
  • Early Virological Response [ Time Frame: 12 weeks ] [ Designated as safety issue: Yes ]
    Proportion of randomized patients achieving early virologic response - negative polymerase chain reaction result for Hepatitis C Virus ribonucleic acid (< 15 IU/ml) or ≥ 2log10 decrease of viral load after 12 weeks of study treatment

  • Early Virological Response in Patients With Different Hepatitis C Virus Genotypes [ Time Frame: 12 weeks ] [ Designated as safety issue: Yes ]
    Proportion of randomized patients with different Hepatitis C Virus (HCV) genotypes achieving early virologic response - negative polymerase chain reaction result for HCV ribonucleic acid (< 15 IU/ml) or ≥ 2log10 decrease of viral load after 12 weeks of study treatment


Secondary Outcome Measures:
  • Rapid Virological Response [ Time Frame: 4 weeks ] [ Designated as safety issue: Yes ]
    Proportion of randomized patients achieving rapid virologic response - negative polymerase chain reaction result for Hepatitis C Virus ribonucleic acid (< 15 IU/ml) after 4 weeks of treatment

  • Rapid Virological Response in Patients With Different Hepatitis C Virus Genotypes [ Time Frame: 4 weeks ] [ Designated as safety issue: Yes ]
    Proportion of randomized patients with different Hepatitis C Virus (HCV) genotypes achieving rapid virological response - negative polymerase chain reaction result for HCV ribonucleic acid (< 15 IU/ml) after 4 weeks of treatment

  • Viral Breakthrough [ Time Frame: screening data and at 4 or 12 weeks of treatment. ] [ Designated as safety issue: Yes ]
    Proportion of patients in each groups with level of Hepatitis C Virus ribonucleic acid > 15 IU/ml after Hepatitis C Virus ribonucleic acid was not present or Hepatitis C Virus ribonucleic acid was increased by more than 1log10 from baseline at 4 or 12 weeks of treatment

  • Biochemical Response [ Time Frame: 12 weeks ] [ Designated as safety issue: Yes ]
    Proportion of patients in each group with alanine aminotransferase level ≤ upper normal limit after 12 weeks of therapy


Enrollment: 140
Study Start Date: September 2013
Estimated Study Completion Date: December 2015
Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Algeron
Algeron at a dose of 1.5 µg/kg of body weight subcutaneously, once a week, and Rebetol, orally, at a daily dose of 800 mg (for body weight <65 kg), 1,000 mg (for body weight 65 - 85 kg), 1,200 mg (for body weight 86 - 105 kg) or 1,400 mg (for body weight > 105 kg)
Drug: Algeron
1.5 µg/kg of body weight subcutaneously, once a week
Other Name: Cepeginterferon alfa-2b
Active Comparator: PegIntron
PegIntron at a dose of 1.5 µg/kg of body weight subcutaneously, once a week, and Rebetol, orally, at a daily dose of 800 mg (for body weight <65 kg), 1,000 mg (for body weight 65 - 85 kg), 1,200 mg (for body weight 86 - 105 kg) or 1,400 mg (for body weight > 105 kg).
Drug: PegIntron
1.5 µg/kg of body weight subcutaneously, once a week
Other Name: peginterferon alfa-2b

Detailed Description:

The course of treatment in both groups shall be 12 weeks, and efficacy analysis, i.e. rate of rapid (after the 4th week) and early (after the 12th week) virologic response will be based on polymerase chain reaction data. For patients with treatment failure after the 12th week the antiviral therapy shall be discontinued. All patients who require further anti-viral treatment will receive a combination treatment with Algeron / PegIntron and ribavirin for another 36 weeks. Sustained virologic response will be assessed 24 weeks after last dose of study treatment.

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Signed Informed Consent Form.
  • Chronic hepatitis C (genotypes 1а, 1b, 2, 3, 4) confirmed by positive result of hepatitis C virus ribonucleic acid during > 6 months before screening visit or accompanied with increase in alanine aminotransferase (ALT) level > 6 months before screening visit.
  • Confirmed Human Immunodeficiency Virus-1 infection based on enzyme-linked immunosorbent assay and immune blotting results.
  • Clinically sustained phase of Human Immunodeficiency Virus-1 infection with absence of active opportunistic Human Immunodeficiency Virus-associated diseases for at least 30 calendar days before inclusion in the study.
  • Level of CD4+-lymphocytes is not less than 500 cells/mm3 for patients not requiring highly active antiretroviral therapy and which will not be assigned to antiretroviral therapy during the study period.
  • For patients receiving sustained highly active antiretroviral therapy for not less than 12 weeks and planning to continue comply with this treatment regimen during the following 24 weeks, level of CD4+-lymphocytes ≥300 cells/mm3, Human Immunodeficiency Virus ribonucleic acid ≤50 copies/ml.
  • Men and women aged 18 to 70 inclusively.
  • Body mass index in the range of 18 - 30 kg/m2 inclusively .
  • Preserved protein-synthetizing liver function (International Normalized Ratio < 1.7, albumin > 35 g/l).
  • Absence of signs of hepatic encephalopathy and ascites according to clinical examination and ultrasound examination.
  • Patients with preserved child-bearing potential and their partners agree to use barrier method of contraception during the whole period of therapy and during 7 months after the treatment completion.
  • Documentary confirmed results of liver elastography (fibroscan) during last year before enrollment in the study or patient agreement to undergo this examination during screening.

Exclusion Criteria:

  • Intolerance of alfa-interferons, ribavirin or any components of tested drug product based on medical history.
  • Presence of hepatitis B, A, E markers.
  • Presence of documentary confirmed clinically significant concurrent liver diseases (alcoholic liver cirrhosis, drug-induced liver cirrhosis, autoimmune hepatitis, hemochromatosis, Wilson's disease, non-alcoholic steatohepatitis, biliary cirrhosis etc.).
  • Past history of Hepatitis C Virus treatment with interferon alfa or pegylated interferon alfa.
  • For patients receiving sustained highly active antiretroviral therapy - presence of nevirapine, stavudine, zidovudine, didanosine in treatment regimen.
  • Use of injectable and non-injectable interferons alfa/ interferon inducers for any indication (except for hepatitis C), radiotherapy, cytotoxic chemotherapy for one month prior to inclusion in the study.
  • Cholestic hepatitis (level of direct bilirubin, alkaline phosphatase, gamma glutamyltransferase, exceeding upper normal limit in > 5 times).
  • Decompensated liver cirrhosis confirmed with results of laboratory analyses (Child-Pugh class B, C) or ultrasound examination.
  • Any documentary confirmed autoimmune diseases (such as Crohn's disease, ulcerative colitis, systemic lupus erythematosus, idiopathic thrombocytopenic purpura, scleroderma, autoimmune hemolytic anemia, severe psoriasis).
  • Deviations of hematologic (hemoglobin less than lower normal limit; neutrophils < 1.5 x 10^9/l; thrombocytes < 90 x 10^9/ l) and biochemical (creatinine level > 1.5 times higher upper normal limit, ALT is > 10 times higher upper normal limit) parameters.
  • Documentary confirmed diagnosis of hemoglobinopathy (for example, thalassemia, sickle-cell anemia).
  • Severe depression, schizophrenia, any other mental disorders which according to the investigator are contraindications for antiviral treatment.
  • Epilepsy and/or central nervous system disorder.
  • Disorder of thyroid function (level of thyroid stimulating hormone out of the normal range).
  • Documentary confirmed or suspected hepatocellular carcinoma based on the results of alfa-fetoprotein (AFP) assay ≥ upper normal limit.
  • Antinuclear antibodies (ANA) titer measured at screening is not less than 1:640 or documentary confirmed signs of autoimmune hepatitis based on the results of biopsy.
  • Documentary confirmed malignant neoplasms.
  • Documentary confirmed lung diseases associated with respiratory failure.
  • Treatment of Human Immunodeficiency Virus-1 with immunotherapeutic vaccines within 90 days prior to screening.
  • Necessity in assignment of antimycobacterial therapy.
  • Pregnancy, lactation period.
  • Documentary confirmed retinopathy (for example, cytomegalovirus retinitis, macular degeneration).
  • Severe concurrent diseases (for example, severe arterial hypertension, sever coronary heart disease, heart failure, decompensated diabetes mellitus and other) which are contraindications for antiviral therapy according to the investigator opinion.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02103439

Locations
Russian Federation
State Public Healthcare Institution National Center for the Prevention and Control of AIDS and other infectious diseases of the Ministry of Health of the Republic of Tatarstan
Kazan, Republic of Tatarstan, Russian Federation, 420097
State Institution of Nizhny Novgorod region "Regional Center for Prevention and Control of AIDS and other infectious diseases"
Nizhny Novgorod, Russian Federation, 603005
State Healthcare Institution Center for the Prevention and Control of AIDS and infectious diseases of the city, St.Petersburg CityHealth Department
Sankt-Petersburg, Russian Federation, 190103
State Budgetary Higher Vocational Education Institution V.I. Razumovsky Saratov State University of medicine
Saratov, Russian Federation, 410012
State Budgetary Higher Vocational Education Institution Pacific State Medical University, Ministry of Health of the Russian Federation
Vladivostok, Russian Federation, 690002
State Healthcare Institution "Volgograd Regional Center for the Prevention and Control of AIDS and infectious diseases"
Volgograd, Russian Federation, 400040
Sponsors and Collaborators
Biocad
Investigators
Principal Investigator: Gregory Moshkovich, M.D. State Institution of Nizhny Novgorod region "Regional Center for Prevention and Control of AIDS and other infectious diseases"
Principal Investigator: Firaya Nagimova, PhD State Public Healthcare Institution National Center for the Prevention and Control of AIDS and other infectious diseases of the Ministry of Health of the Republic of Tatarstan
Principal Investigator: Oleg Kozyrev, PhD State Healthcare Institution "Volgograd Regional Center for the Prevention and Control of AIDS and infectious diseases"
Principal Investigator: Andrey Shuldyakov, M.D., PhD State Budgetary Higher Vocational Education Institution V.I. Razumovsky Saratov State University of medicine
Principal Investigator: Vadim Rassokhin, PhD State Healthcare Institution Center for the Prevention and Control of AIDS and infectious diseases of the city, St.Petersburg CityHealth Department
Principal Investigator: Lidia Sklar, M.D., PhD State Budgetary Higher Vocational Education Institution Pacific State Medical University, Ministry of Health of the Russian Federation
  More Information

No publications provided

Responsible Party: Biocad
ClinicalTrials.gov Identifier: NCT02103439     History of Changes
Other Study ID Numbers: BCD-016-4
Study First Received: April 1, 2014
Results First Received: May 21, 2015
Last Updated: July 22, 2015
Health Authority: Russia: Ministry of Health of the Russian Federation

Keywords provided by Biocad:
Hepatitis C
Cepeginterferon alfa
Peginterferon
Treatment

Additional relevant MeSH terms:
Acquired Immunodeficiency Syndrome
Coinfection
HIV Infections
Hepatitis
Hepatitis A
Hepatitis C
Hepatitis C, Chronic
Hepatitis, Chronic
Immunologic Deficiency Syndromes
Digestive System Diseases
Enterovirus Infections
Flaviviridae Infections
Hepatitis, Viral, Human
Immune System Diseases
Infection
Lentivirus Infections
Liver Diseases
Parasitic Diseases
Picornaviridae Infections
RNA Virus Infections
Retroviridae Infections
Sexually Transmitted Diseases
Sexually Transmitted Diseases, Viral
Slow Virus Diseases
Virus Diseases
Interferon-alpha
Peginterferon alfa-2b
Anti-Infective Agents
Antiviral Agents
Immunologic Factors

ClinicalTrials.gov processed this record on August 27, 2015